Resources
7 Results (showing 1 - 7)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 10/10/2023 (updated 3/27/2024)
Researchers analyzed survey responses to the 2021 Public Health Workforce Interest and Needs Survey to compare rural and urban skill proficiencies, training needs, turnover risk, and experiences of bullying due to work as a public health professional. Among the findings, rural staff had higher likelihood than urban staff of reporting proficiencies in community engagement, data-based decision-making, and in diversity, equity, and inclusion. Rural staff were also more likely than urban staff to report leaving because of stress, experiences of bullying, and avoiding situations that made them think about COVID-19.
Posted 1/31/2023 (updated 3/27/2024)
There are systemic barriers in hospital-based addiction medicine that can lead to symptoms of burnout among medical professionals. The qualitative study highlights these factors that may contribute to burnout and provides some feedback on how to work towards minimizing this for providers.
Posted 5/22/2020 (updated 3/28/2024)
To identify Finnegan Neonatal Abstinence Scoring Tool tems independently associated with the decision to use pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the treatment decision.
Posted 10/12/2020 (updated 3/29/2024)
The present two-fold study “Speed Limits – Harm reduction for people who use stimulants” significantly contributes to closing the gap of knowledge about which existing harm reduction interventions are effective for people who use stimulant drugs.
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 4/19/2021 (updated 4/5/2024)
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed